Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Aetna Picks Gilead Sciences Hepatitis C Drugs Over Abbvie’s

By Drug Discovery Trends Editor | January 20, 2015

Insurer Aetna has made new hepatitis C drugs from Gilead Sciences Inc. preferred treatments for customers with the liver-destroying virus.
 
Aetna Inc. said that it’s reached a deal with Gilead bringing discounts for Sovaldi and Harvoni, which have list prices of about $84,000 and $94,000, respectively, for a course of treatment. The amount of the discount wasn’t disclosed.
 
Aetna’s decision follows moves by two huge prescription benefit managers, Express Scripts Holdings Co. and CVS Health Corp., to wring big discounts from makers of a new generation of hepatitis C medicines that cure nearly all patients, in as little as eight weeks. Besides Gilead’s medicines, AbbVie Inc.’s combo treatment, Viekira Pak, was launched last month with a list price of about $83,300.
 
Aetna’s deal affects customers who get their health care coverage from an employer or a health care exchange, or just over 10.8 million people, according to a company spokeswoman.
 
Patients must go through Aetna’s preauthorization process before they can fill prescriptions for any hepatitis C drugs, including older, less-expensive ones.
 
Earlier treatment regimens require taking both pills and injected drugs, cause nasty flu-like symptoms and other side effects many patients can’t tolerate, and require treatment for up to a year – yet those regimens still barely cure half of patients.
 
The new Gilead and AbbVie pills are tremendous improvements. But their eye-popping prices – $1,000 a pill for Sovaldi, for example – have galvanized health insurers and prescription benefit managers to demand big discounts to include the drugs on their formularies of preferred medicines, or to restrict coverage to just one company’s treatments.
 
That’s because about 3.2 million Americans are infected with hepatitis C, which generally doesn’t cause noticeable symptoms until the liver is damaged. Without proper treatment, up to 30 percent of those people will eventually develop cirrhosis, or scarring of the liver tissue. The virus can cause liver failure and liver cancer, resulting in the need for a liver transplant. That all runs up a much bigger bill than the new medicines will, which is how the drugmakers seek to justify their high prices.
 
The pushback from payers comes as much of the pharmaceutical industry is focused on developing ultra-expensive medicines – some costing hundreds of thousands of dollars a year – for various cancers, hepatitis C and many diseases that are rare individually, but as a group affect tens of millions of Americans.
 
Aetna is based in Hartford, Connecticut.

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50